Last reviewed · How we verify
Bailing Capsules in combination Guben Kechuan Granules
Bailing Capsules in combination with Guben Kechuan Granules, developed by the Second Affiliated Hospital, School of Medicine, Zhejiang University, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its unique combination therapy, which differentiates it in the market. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Bailing Capsules in combination Guben Kechuan Granules |
|---|---|
| Also known as | Bailing Capsules, Guben Kechuan Granules |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: